CLEVELAND, Sept. 1, 2015 /PRNewswire/ -- GenomOncology today announced that Benjamin Salisbury, Ph.D., has joined the company as Vice President, New Products and Marketing. In this position, Dr. Salisbury will be responsible for GenomOncology's corporate and product marketing and for bringing to market new products that build upon the company's precision medicine technology.
Dr. Salisbury has been in the precision medicine industry for 14 years. He joins GenomOncology from Knome, where he guided the transition of the company's research-focused, internal-use software for next generation sequencing analysis to a product that supports clinical laboratory operations. He also has held several management and scientific positions at Transgenomic, PGxHealth, and Genaissance Pharmaceuticals.
As a scientist, Dr. Salisbury's expertise includes molecular diagnostics, pharmacogenomics, population genetics, statistical genetics, and algorithm development. He has authored over 30 peer-reviewed publications in these and other fields. He serves as an adjunct faculty member in the Biomedical Sciences Program at Wright State University. Dr. Salisbury received a B.A. in Biology from Yale University and a Ph.D. in Biology from the University of Michigan. He was a guest researcher in the Department of Systematic Botany at Lund University in Sweden, and was a Postdoctoral Fellow in the Department of Ecology and Evolutionary Biology at Yale University.
The creation of this new position represents the third expansion of GenomOncology's management team in recent months. The hiring of Dr. Salisbury was preceded by the recruitment of Dr. Condie Carmack, VP of Translational Medicine, and Baiju Parikh, VP of Sales. "We are delighted to be attracting such experienced executive and scientific talent to GenomOncology. Our ability to do so reflects the company's compelling story and supports its rapid commercial growth," said Manuel Glynias, President and CEO of GenomOncology.
GenomOncology is a healthcare technology company dedicated to enabling precision medicine by transforming genetic data into actionable information. The GO Precision Medicine Portfolio™ is trusted by molecular pathologists and medical geneticists for streamlined development and production of knowledge- and guideline-driven cancer and hereditary disease tests. GenomOncology's technology allows multiple modes of genetic analysis to fuel integrated clinical decision support and research built on accumulating experience. Learn more at www.genomoncology.com.
CONTACT: [email protected], 440-617-6087